Mayne Pharma Group Ltd
ASX:MYX
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Deere & Co
NYSE:DE
|
Machinery
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Duke Energy Corp
NYSE:DUK
|
Utilities
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Monster Beverage Corp
NASDAQ:MNST
|
Beverages
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.81
7.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Deere & Co
NYSE:DE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Duke Energy Corp
NYSE:DUK
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Monster Beverage Corp
NASDAQ:MNST
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Mayne Pharma Group Ltd
Mayne Pharma Group Ltd
Income from Continuing Operations
Mayne Pharma Group Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Income from Continuing Operations
-AU$168.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Income from Continuing Operations
AU$117.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Income from Continuing Operations
-AU$13.9m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-38%
|
|
|
Probiotec Ltd
ASX:PBP
|
Income from Continuing Operations
AU$8.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Income from Continuing Operations
AU$9.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
44%
|
CAGR 10-Years
3%
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Income from Continuing Operations
-AU$8.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Mayne Pharma Group Ltd
Glance View
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
See Also
What is Mayne Pharma Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
-168.6m
AUD
Based on the financial report for Jun 30, 2024, Mayne Pharma Group Ltd's Income from Continuing Operations amounts to -168.6m AUD.
What is Mayne Pharma Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
10%
Over the last year, the Income from Continuing Operations growth was 47%. The average annual Income from Continuing Operations growth rates for Mayne Pharma Group Ltd have been 7% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
